Anti-AXL biologic increases tumor sensitivity to radiation and check-point inhibitors

(Kureczka/Martin Associates) Aravive-S6 selectively inhibits the AXL-signaling pathway that acts as a 'survival switch' that promotes tumor growth and metastasis, and resistance to common chemotherapeutic agents. New research adds to evidence that AXL over-expression also results in tumor unresponsiveness to radiation and check-point inhibitors, and further shows that inhibiting AXL signaling elicits an anti-tumor immune response and sensitizes tumors to radiation and other anticancer therapies ...